Galmed Pharmaceuticals

Galmed Pharmaceuticals

Galmed Pharmaceuticals was founded in 2003 in Tel Aviv by Dr. Allen Baharaff, who continues as President and CEO. The company emerged from early-stage metabolic research and has remained narrowly focused on a single synthetic bile-acid conjugate, Aramchol, targeting non-alcoholic steatohepatitis (NASH), a complex liver disease with no approved therapies as of mid-decade. The wealth origin is not family-office linked; Galmed has operated as a publicly traded clinical-stage entity since its 2014 Nasdaq listing. The firm's deployment is entirely clinical: advancing Aramchol through Phase 3 and open-label extension studies, including the pivotal ARMOR trial and the global ARREST study. The asset-class mix is singular — biotech drug development — with no direct co-investments, SPVs, or fund-of-funds structures. Geographic footprint spans Israel-based R&D and US-facing regulatory and capital-markets activity, with trial sites across North America, Europe, and Israel. Galmed's strategy hinges on differentiating Aramchol's mechanism — SCD1 modulation — from the FXR agonists and GLP-1-adjacent competitors discontinued by Intercept, Genfit, and CymaBay. Scale is measured in clinical milestones rather than headcount. Galmed has historically operated a lean team common to Israeli biotechs, outsourcing manufacturing and trial logistics while retaining scientific oversight in Tel Aviv. In May 2024, the company announced a 1-for-15 reverse stock split to regain Nasdaq compliance, a restructuring signal common among capital-constrained biotechs. The firm's adjacent vehicle is its dual-listed status, with ordinary shares traded on Nasdaq under the ticker GLMD. Galmed's structural differentiator is its contrarian persistence in a therapeutic area largely abandoned by deep-pocketed competitors. While larger NASH players pivoted, Galmed amassed multi-year open-label safety data that serves as a moat against new entrants. The single-asset concentration creates binary risk absent from diversified life-science portfolios.